Association between the preoperative Midkine (+)/CEA (+) level and poor prognosis in colorectal cancer patients.

IF 1.6 4区医学 Q2 SURGERY

Surgery Today Pub Date : 2025-10-01 Epub Date: 2025-04-23 DOI:10.1007/s00595-025-03044-8

Mitsunori Ushigome, Hideaki Shimada, Masaaki Ito, Kimihiko Yoshida, Takayuki Suzuki, Satoru Kagami, Yasuyuki Miura, Tomoaki Kaneko, Akiharu Kurihara, Kimihiko Funahashi

{"title":"Association between the preoperative Midkine (+)/CEA (+) level and poor prognosis in colorectal cancer patients.","authors":"Mitsunori Ushigome, Hideaki Shimada, Masaaki Ito, Kimihiko Yoshida, Takayuki Suzuki, Satoru Kagami, Yasuyuki Miura, Tomoaki Kaneko, Akiharu Kurihara, Kimihiko Funahashi","doi":"10.1007/s00595-025-03044-8","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the clinicopathological and prognostic significance of preoperative serum Midkine levels in patients with colorectal cancer.Methods: Preoperative Midkine levels were analyzed using an enzyme-linked immunosorbent assay in 78 patients with colorectal cancer, at stages 0 (n = 2), I (n = 19), II (n = 25), III (n = 24), and IV (n = 8). Using a cut-off value of 421 pg/mL, the patients were divided into a Midkine(+) group and a Midkine(-) group. Clinicopathological factors and prognosis were compared between the two groups, using univariate and multivariate analyses.Results: The overall positive rates were 46%, 32%, and 21% for CEA, Midkine, and CA19-9, respectively. The positive rate of the Midkine/CEA combination was 55%. The positive rates at stage 0/I were 19%, 19%, and 5% for CEA, Midkine, and CA19-9, respectively. The Midkine(+) group showed poor survival, but the differences were not significant. The Midkine (+)/CEA (+) group had significantly worse relapse-free survival (RFS) (p = 0.02). The Midkine (+)/CEA (+) level was an independent risk factor for RFS (p = 0.04) and overall survival (p = 0.03).Conclusion: The Midkine (+)/CEA (+) combination may be an indicator of poor prognosis for patients with colorectal cancer.","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":"1421-1429"},"PeriodicalIF":1.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery Today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00595-025-03044-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the clinicopathological and prognostic significance of preoperative serum Midkine levels in patients with colorectal cancer.

Methods: Preoperative Midkine levels were analyzed using an enzyme-linked immunosorbent assay in 78 patients with colorectal cancer, at stages 0 (n = 2), I (n = 19), II (n = 25), III (n = 24), and IV (n = 8). Using a cut-off value of 421 pg/mL, the patients were divided into a Midkine(+) group and a Midkine(-) group. Clinicopathological factors and prognosis were compared between the two groups, using univariate and multivariate analyses.

Results: The overall positive rates were 46%, 32%, and 21% for CEA, Midkine, and CA19-9, respectively. The positive rate of the Midkine/CEA combination was 55%. The positive rates at stage 0/I were 19%, 19%, and 5% for CEA, Midkine, and CA19-9, respectively. The Midkine(+) group showed poor survival, but the differences were not significant. The Midkine (+)/CEA (+) group had significantly worse relapse-free survival (RFS) (p = 0.02). The Midkine (+)/CEA (+) level was an independent risk factor for RFS (p = 0.04) and overall survival (p = 0.03).

Conclusion: The Midkine (+)/CEA (+) combination may be an indicator of poor prognosis for patients with colorectal cancer.

查看原文本刊更多论文

结直肠癌患者术前Midkine (+)/CEA（+）水平与不良预后的关系

目的：探讨大肠癌患者术前血清Midkine水平的临床病理及预后意义。方法：采用酶联免疫吸附法分析78例0期（n = 2）、1期（n = 19）、2期（n = 25）、3期（n = 24）和4期（n = 8）结直肠癌患者的术前Midkine水平。采用截断值421 pg/mL，将患者分为Midkine（+）组和Midkine（-）组。采用单因素和多因素分析比较两组患者的临床病理因素及预后。结果：CEA、Midkine和CA19-9的总阳性率分别为46%、32%和21%。Midkine/CEA联合阳性率为55%。0/I期CEA、Midkine和CA19-9的阳性率分别为19%、19%和5%。Midkine（+）组生存率较差，但差异不显著。Midkine (+)/CEA（+）组无复发生存期（RFS）显著差（p = 0.02）。Midkine (+)/CEA（+）水平是RFS （p = 0.04）和总生存率（p = 0.03）的独立危险因素。结论：Midkine (+)/CEA（+）联合可能是判断结直肠癌患者预后不良的一个指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgery Today 医学-外科

CiteScore

4.90

自引率

4.00%

发文量

208

审稿时长

1 months

期刊介绍： Surgery Today is the official journal of the Japan Surgical Society. The main purpose of the journal is to provide a place for the publication of high-quality papers documenting recent advances and new developments in all fields of surgery, both clinical and experimental. The journal welcomes original papers, review articles, and short communications, as well as short technical reports("How to do it"). The "How to do it" section will includes short articles on methods or techniques recommended for practical surgery. Papers submitted to the journal are reviewed by an international editorial board. Field of interest: All fields of surgery.